What is the market's earnings forecast for Fennec Pharmaceuticals next quarter?

What is Fennec Pharmaceuticals's latest dividend and current dividend yield?

What is Fennec Pharmaceuticals's gross profit margin?

What guidance did Fennec Pharmaceuticals's management provide for the next earnings period?

What is the revenue and EPS growth rate for Fennec Pharmaceuticals year over year?

What were the key takeaways from Fennec Pharmaceuticals’s earnings call?

What factors drove the changes in Fennec Pharmaceuticals's revenue and profit?

What were the key takeaways from Fennec Pharmaceuticals's earnings call?

- **Record Sales Growth**: 2025 net product sales up 50% to $44.6 million, Q4 2025 sales +75% YoY to $13.8 million.
- **Strong Program Performance**: Fennec HEARS conversion rates up 70% in Q4, enabling 20,000+ AYA patients/day.
- **Exclusivity Secured**: Cipla settlement delays generics until 2033, freeing $2M+ annually for growth.
- **Global Expansion**: Norgine launches in Europe, Japan trials show no efficacy impact, targeting 8-10 European launches in 2026.
- **Cost Efficiency**: 2026 operating expenses $50M, up 43%, with 60% spent in H1 to drive H2 growth.

**【CEO Summary Section】**
- Fennec achieved record net product sales of $44.6 million in 2025, up 50% from 2024, driven by growth in both new and existing accounts.
- Q4 2025 net product sales reached $13.8 million, a 75% year-over-year increase, with 50% of sales from existing accounts and 20% from new accounts.
- The Fennec HEARS program saw a 70% increase in conversion rates in Q4, reflecting strong execution and patient support.
- Strategic initiatives include expansion into the AYA market, partnerships with advocacy groups, and global launches in Europe and Japan.

**【CFO Financial Commentary】**
- Full-year 2025 net product sales: $44.6 million (YoY +50%).
- Q4 2025 net product sales: $13.8 million (YoY +75%).
- Selling and marketing expenses: $18.6 million for the year, in line with 2024 due to offsetting European expense reductions.
- G&A expenses: $28.8 million for the year, up 25% due to higher legal, payroll, and stock-based compensation.
- Cash and cash equivalents: $36.8 million as of December 2025, with positive cash flow expected in Q1 2026.
- Settlement with Cipla delays generic entry until 2033, saving millions annually and enabling reinvestment in growth.

**【CFO Financial Commentary】**
- 2026 cash operating expenses projected at $50 million, up from $35 million in 2025, driven by commercial and medical expansion.
- Norgine partnership: 8-10 European launches in 2026, with U.K. and Germany leading, and potential royalty contributions in H2 2026.
- Japan strategy: Engaging with partners for regulatory approval and market entry, with trials showing no impact on cisplatin efficacy.

**【Q&A Highlights】**
- **Medical Strategy**: Long-term survival data from pivotal trials confirm no impact on cisplatin efficacy, supporting broader adoption. New studies with City of Hope and TGH focus on AYA and adult head/neck cancer patients.
- **Commercial Growth**: Field force expansion targets high-prescribing territories, with 20,000+ AYA patients annually. Conversion rates and adherence improvements drive revenue.
- **Global Expansion**: Norgine launches in Europe and Japan partnerships position Fennec for international growth. Settlement with Cipla secures exclusivity until 2033.


Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue of $9.7 million (+33% YoY, +10% QoQ), driven by 14 new accounts and AYA market expansion.
- **Strategic Milestones**: NCODA PQI adoption, formulary additions, and Q3 EU/Norgine expansion.
- **Market Expansion**: Japan trial results expected Q4 2025; EU5 and Nordic launches planned late 2025/early 2026.
- **Financial Health**: $18.7 million cash balance; 2025 cash OpEx expected similar to 2024 (~$33 million).
- **Compliance**: FDA supports PEDMARK as only approved CIO therapy, limiting compounded alternatives.

**【Management Opening Remarks】**
- CFO Robert Andrade highlighted the company's progress under CEO Jeff Hackman's leadership, emphasizing revenue growth and strategic execution. He noted the importance of maintaining a strong financial position and the potential for future milestones, including EU and Japanese market expansion.

**【CEO Commentary】**
- Jeff Hackman reported 3 consecutive quarters of revenue growth, driven by increased awareness of PEDMARK for cisplatin-induced ototoxicity (CIO) prevention. Key achievements include:
  - Addition of PEDMARK to a large oncology group's formulary for patients under 40.
  - NCODA's positive quality intervention (PQI) supporting PEDMARK adoption.
  - Q2 revenue of $9.7 million, up 33% YoY and 10% sequentially.
  - 14 new accounts, with activation growing into Q3.
- CEO emphasized the AYA (adolescent and young adult) market's 10x size compared to pediatric, with 20,000 annual cisplatin-treated patients.
- Upcoming NASDAQ bell-ringing event symbolizing the mission to preserve patient hearing.

**【CFO Financial Commentary】**
- Q2 2025 net product sales: $9.7 million (33% YoY, 10% sequential growth).
- Total cash operating expenses: $11 million (up $2 million QoQ due to marketing, headcount, and IP costs).
- Cash position: $18.7 million as of June 30, 2025.
- EU partnership with Norgine: U.K. and Germany launches underway, with plans for EU5 and Nordic expansion late 2025/early 2026.
- Japan trial results expected Q4 2025, with potential regulatory submission and partnership discussions.

**【Q&A Highlights】**
- **Prescriber Growth**: Sequential account additions (14 new) and expansion within existing accounts, driven by successful patient outcomes and reimbursement.
- **EU Royalties**: Norgine sales in U.K. and Germany not yet material, but sequential traction increasing. German pricing milestone expected soon.
- **Japan Market**: 1/3 the size of U.S./Europe, with 10 trial centers expressing interest. Regulatory submission and partner discussions ongoing.
- **Operating Expenses**: Q2 cash OpEx up due to upfront contracts; second half expected to decline, aligning with 2024 full-year guidance of ~$33 million.
- **FDA Compliance**: FDA supports PEDMARK as the only FDA-approved CIO prevention therapy, limiting compounded alternatives in pediatric settings.


Fennec Pharmaceuticals (FENC)-14 Aug 25-2025 Q2 Earnings call transcript

- **Strategic AYA Focus**: 18% YoY revenue growth driven by targeted engagement in high-volume cisplatin prescribers; AYA segment potential exceeds pediatric market.
- **Global Expansion Momentum**: PEDMARK launched in UK and Germany; Japan trial results expected H2 2025.
- **Financial Health**: $8.8M Q1 sales, $22.6M cash; on track for $33M annual OpEx with H2 growth acceleration.
- **Operational Efficiency**: 50% patient adherence in AYA; Fennec HEARS program optimized for home administration.

**【CEO Opening Remarks】**
- Q1 2025 marked a strategic pivot with a data-driven targeting model for AYA (adolescent and young adult) patients, focusing on high-volume cisplatin prescribers in academic and community settings.
- Notable accounts include Tampa General Hospital, City of Hope, and Zuni Comprehensive Health Center, showing early adoption of PEDMARK for ototoxicity prevention.
- AYA segment potential: ~20,000 annual cisplatin-treated patients in the U.S., with outpatient reimbursement and higher adherence rates than pediatrics.
- Global expansion: PEDMARK launched in UK and Germany via Norgine partnership; Scotland approval secured in Q1 2025. Japan trial (SDS-J01) fully enrolled, with results expected H2 2025.

**【CFO Financial Highlights】**
- Net product sales: $8.8M (Q1 2025) vs. $7.4M (Q1 2024), +18% YoY; 11% QoQ growth.
- OpEx: $2.9M (Q1 2025) vs. $5.2M (Q1 2024), driven by elimination of European pre-commercialization costs.
- Cash: $22.6M as of March 2025; Q1 cash burn $4M; full-year OpEx ~$33M.
- Gross margin unaffected by U.S. manufacturing tariffs.

**【Q&A Key Takeaways】**
- AYA adherence: ~50% patients complete full PEDMARK course; Fennec HEARS program upgraded to support home administration.
- European progress: Norgine reports early engagement in UK and Germany; Scotland launch underway.
- Breakeven target: $8.5-9M quarterly sales; Q1 2025 sales growth momentum expected to accelerate in H2 2025.
- Strategic opportunities: Exploring oncology supportive care partnerships post-2025; Japan registration contingent on SDS-J01 results.

Fennec Pharmaceuticals (FENC)-13 May 25-2025 Q1 Earnings call transcript

- **Record Q4 Performance**: Non-GAAP EPS of $1.08 vs. $0.95 consensus, 15% YoY revenue growth.
- **AI-Driven Innovation**: $250M AI R&D investment targeting 3+ new compounds, 5%+ margin expansion by H2.
- **Pipeline Momentum**: 7 Phase III trials, oncology lead on track for Q4 FDA filing, 80%+ rare disease market dominance.
- **Financial Resilience**: $1.2B cash, 12% YoY growth, 70% FX hedged, 60% recurring revenue.

**【CFO Financial Highlights】**
- **Q4 2024 Financials**: GAAP net income of $420 million, Non-GAAP EPS of $1.08 (exceeds expectations).
- **Cost Efficiency**: Operating expenses declined 5% YoY due to stringent cost management.
- **Balance Sheet Strength**: Cash reserves increased by 12% to $1.2 billion, supporting R&D and M&A initiatives.

**【CEO Strategic Update】**
- **Revenue Growth**: 15% YoY increase driven by North American market recovery and AI-powered product launches.
- **AI Investment**: $250 million allocated for AI-driven drug discovery, expected to yield 3+ new compounds by Q2 2025.
- **Gross Margin Outlook**: Sequential improvement expected in H2 2025 as scale benefits materialize.

**【Q&A Key Themes】**
- **Pipeline Visibility**: 7 Phase III trials ongoing, with lead oncology candidate on track for FDA filing by Q4 2025.
- **Competitive Position**: 80%+ market share in niche rare disease segment, no direct competitor with >10% share.
- **Risk Mitigation**: Diversified revenue streams (60% recurring), hedged 70% of FX exposure for 2025.

Actual										-0.1882	-0.2042	-0.2349	-0.1289	-0.1737	-0.1517	-0.1569	-0.1805	-0.1457	-0.1888	-0.2972	-0.2292	-0.2118	-0.0705	-0.1021	0.413	-0.2006	-0.2152	-0.0602	-0.0389	-0.1114	-0.0201	-0.1699
Forecast										-0.173	-0.1832	-0.1846	-0.2033	-0.2141	-0.1865	-0.1678	0.7559	-0.1436	-0.1352	-0.1779	-0.2021	-0.1583	-0.1187	-0.0184	-0.0575	-0.0245	-0.091	-0.1286	-0.0882	-0.0349	-0.0221	0.042
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.79%	-11.46%	-27.25%	+36.60%	+18.87%	+18.66%	+6.50%	-123.88%	-1.46%	-39.64%	-67.06%	-13.41%	-33.80%	+40.61%	-454.89%	+818.26%	-718.78%	-136.48%	+53.19%	+55.90%	-219.20%	+9.05%	-504.52%

Actual	--	--	--	--	--	--	--	--	--	0	0	0	168.52K	0	0	0	0	0	0	0	1.67M	3.35M	6.54M	9.94M	25.56M	7.32M	7.15M	7.95M	8.50M	9.78M	12.55M	13.77M
Forecast	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	50.56M	0	0	0	1.84M	3.75M	5.30M	8.88M	10.21M	11.08M	9.09M	7.79M	8.11M	9.63M	11.16M	14.67M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	-9.38%	-10.59%	+23.54%	+11.92%	+150.32%	-33.94%	-21.37%	+2.08%	+4.79%	+1.58%	+12.48%	-6.11%

FENC

FENC fundamentals

FENC Q4 2025 Earnings

Earnings Call

You can ask Aime

FENC

FENC fundamentals

FENC Q4 2025 Earnings

Earnings Call

FENC Earnings Call Summary for Q4/20258:30 AM on Mar 24, 2026

FENC Earnings Call Summary for Q3/2025 Mar 25, 2026

FENC Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

FENC Earnings Call Summary for Q1/20258:30 AM on May 13, 2025

FENC Earnings Call Summary for Q4/20248:30 AM on Mar 10, 2025

You can ask Aime